Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How do low-molecular-weight heparin and unfractionated heparin compare following ST-segment elevation MI?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 244–245 (2006)Cite this article

boxed-textSabatine MS et al. (2005) Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation 112: 3846–3854

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Antman EM et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 44: 671–719

    Article  Google Scholar 

  2. Eikelboom JW et al. (2005) Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 112: 3855–3867

    Article  CAS  Google Scholar 

  3. Yusuf S et al. (2005) Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 293: 427–435

    Article  CAS  Google Scholar 

  4. Metz BK et al. (1998) Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. J Am Coll Cardiol 31: 1493–1498

    Article  CAS  Google Scholar 

  5. White H (2001) Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 358: 1855–1863

    Article  CAS  Google Scholar 

  6. Andre P et al. (2003) Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 108: 2697–2703

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor of Medicine and Director of Cardiovascular Education & Clinical Research in the Department of Medicine at the Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, KY, USA

    Steven R Steinhubl

Authors
  1. Steven R Steinhubl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven R Steinhubl.

Ethics declarations

Competing interests

SR Steinhubl has received honorarium from Sanofi-Aventis, the Medicines Company, AstraZeneca and Eli Lilly.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinhubl, S. How do low-molecular-weight heparin and unfractionated heparin compare following ST-segment elevation MI?. Nat Rev Cardiol 3, 244–245 (2006). https://doi.org/10.1038/ncpcardio0542

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0542

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing